Evidence map›Paper›PMID 35477193›Full record

ArticleZhongguo fei ai za zhi = Chinese journal of lung cancer2022

[Two Case Reports of Type 2 Diabetes Induced by Immune Checkpoint Inhibitors 
Combined with Chemotherapy].

Ping Xiao, Linlin Zhang, Yu Wang, Fanlu Meng, Xin Wang, Diansheng Zhong

Open access · greenAbstract readCase Reports
In one paragraph

Article in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Ping XiaoDepartment of Medical Oncology, 
Tianjin Medical University General Hospital, Tianjin 300052, China.
Linlin ZhangDepartment of Medical Oncology, 
Tianjin Medical University General Hospital, Tianjin 300052, China.
Yu WangDepartment of Medical Endocrine Metabolism, 
Tianjin Medical University General Hospital, Tianjin 300052, China.
Fanlu MengDepartment of Medical Oncology, 
Tianjin Medical University General Hospital, Tianjin 300052, China.
Xin WangDepartment of Medical Oncology, 
Tianjin Medical University General Hospital, Tianjin 300052, China.
Diansheng ZhongDepartment of Medical Oncology, 
Tianjin Medical University General Hospital, Tianjin 300052, China.
Tianjin Medical University General Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICIs) have become an important means of cancer treatment, and their application in the clinic is becoming more and more widespread. The adverse reactions caused by ICIs are gradually recognized. Among them, immunotherapy-related diabetes is a rare adverse reaction and type 1 diabetes mellitusis common. With the wide application of ICIs combined with chemotherapy in lung cancer patients, patients with type 2 diabetes mellitus have gradually been discovered during the treatment. However, the effect of continued use of ICIs maintenance therapy on blood glucose and ICIs treatment process in these patients is still unclear. This article reports two cases of type 2 diabetes mellitus induced by immune checkpoint inhibitor combined with chemotherapy, one of whom converted to type 1 diabetes mellitus, in order to increase the understanding of immunotherapy-related diabetes.
.

Indexed as

Diabetes Mellitus, Type 2Lung NeoplasmsHumansImmune Checkpoint InhibitorsImmunotherapyMolecular Targeted TherapyImmune Checkpoint InhibitorsAdverse reactionImmune checkpoint inhibitorsType 2 diabetes mellitus

Identifiers

PMID35477193
PMCPMC9051303
OpenAlexW4225091981

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.